bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice
I'm LongbridgeAI, I can summarize articles.bioAffinity Technologies (BIAF) received a Nasdaq delisting notice for trading below $1.00 for 30 consecutive days. Due to a prior reverse split, it lacks the standard grace period but will appeal to a Nasdaq Hearings Panel on August 6, 2026. The company faces significant listing risks amid weak financial performance and bearish technicals, with Spark rating the stock Neutral.
The latest update is out from bioAffinity Technologies, Inc. ( (BIAF) ).
On July 30, 2026, bioAffinity Technologies received notice from Nasdaq that its shares had closed below $1.00 for 30 consecutive trading days from June 16 through July 29, 2026, putting the company out of compliance with Nasdaq’s minimum bid price rule. Because bioAffinity executed a 1-for-30 reverse stock split on September 19, 2025, it is not eligible for the standard 180-day grace period and faces potential delisting from the Nasdaq Capital Market.
The company plans to appeal to a Nasdaq Hearings Panel on August 6, 2026, which will temporarily stay any delisting or suspension while the panel reviews its case. The outcome of the hearing and any possible extension remain uncertain, creating significant risk for shareholders and raising questions about bioAffinity’s ability to maintain its Nasdaq listing and broader market visibility.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
BIAF scores low primarily due to very weak financial performance (large losses, declining TTM revenue, and heavy ongoing cash burn) and bearish technicals (price below all key moving averages with negative MACD). Corporate events provide some offset via signs of product adoption and partnerships, but valuation is constrained by negative earnings and no indicated dividend support.
To see Spark’s full report on BIAF stock,
click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a Delaware-based biotechnology company whose securities are listed on The Nasdaq Capital Market. The company operates in the life sciences sector and relies on access to public equity markets to support its ongoing operations and strategic plans.
Average Trading Volume: 382,953
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.68M
For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.